The phase 3 clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled multicenter study, according to the report. During phase 2 clinical trials, Remimazolam was found to have a faster onset of sedation and faster patient recovery in comparison to midazolam.
The phase 3 clinical trial will include 460 patients undergoing diagnostic and therapeutic colonoscopy.
More articles on gastroenterology:
Boston Scientific CEO says medical device tax hinders industry
18 statistics on gastroenterologist habits & burnout
6 gastroenterologists making headlines – March 27, 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
